株式会社PRISM BioLab Logo

株式会社PRISM BioLab

A biotech creating novel drugs by targeting previously "undruggable" protein interactions.

206A | T

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
Japan
Address:
藤沢市村岡東二丁目26番1号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

PRISM BioLab is a biotechnology company dedicated to creating novel small molecule drugs for diseases that currently lack effective treatments. The company's core is its proprietary PepMetics® drug discovery platform, which enables the targeting of previously "undruggable" proteins. This technology utilizes unique small molecule scaffolds that mimic peptide structures (α-helices and β-turns) to control protein-protein interactions (PPIs), a key cause of many diseases. By making these challenging targets accessible, PRISM BioLab aims to pioneer new therapies and collaborates with pharmaceutical companies to advance its drug discovery programs.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-07-17 09:30
Major Shareholding Notification
臨時報告書
Japanese 21.0 KB
2025-05-14 09:31
Registration Form
確認書
Japanese 8.7 KB
2025-05-14 09:30
Interim Report
半期報告書-第14期(2024/10/01-2025/09/30)
Japanese 224.7 KB
2024-12-27 07:34
Regulatory News Service
内部統制報告書-第13期(2023/10/01-2024/09/30)
Japanese 22.2 KB
2024-12-27 07:33
Registration Form
確認書
Japanese 8.7 KB
2024-12-27 07:32
Annual Report
有価証券報告書-第13期(2023/10/01-2024/09/30)
Japanese 3.1 MB
2024-12-27 07:31
Post-Annual General Meeting Information
臨時報告書
Japanese 22.1 KB
2024-11-14 07:32
Regulatory News Service
臨時報告書
Japanese 20.8 KB
2024-10-16 10:12
Major Shareholding Notification
臨時報告書
Japanese 20.7 KB
2024-09-10 09:09
Regulatory News Service
臨時報告書
Japanese 19.9 KB
2024-06-24 08:00
Prospectus
訂正有価証券届出書(新規公開時)
Japanese 2.2 MB
2024-06-14 08:00
Registration Form
訂正有価証券届出書(新規公開時)
Japanese 2.3 MB
2024-05-27 08:00
Registration Form
有価証券届出書(新規公開時)
Japanese 4.3 MB

Automate Your Workflow. Get a real-time feed of all 株式会社PRISM BioLab filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for 株式会社PRISM BioLab via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Corline Biomedical AB Logo
Develops heparin-based coatings for medical device biocompatibility and regenerative medicine.
Sweden CLBIO
Cosma Spolka Akcyjna Logo
Produces natural hemp supplements and pharmaceutical raw materials for retail & wholesale markets.
Poland COS
COSMO Pharmaceuticals N.V. Logo
Specialty pharma for gastroenterology/dermatology, offering colon treatments & manufacturing services.
Netherlands COPN
Crossject Logo
Develops needle-free auto-injectors for rapid drug delivery in medical emergencies.
France ALCJ
CTC BIO, INC. Logo
Develops pharmaceuticals and feed additives for human and animal health using fermentation tech.
South Korea 060590
Cuorips Inc. Logo
Develops iPS cell therapies, like a cardiomyocyte sheet for severe heart failure.
Japan 4894
curacle co., ltd. Logo
Developing drugs for intractable diseases like diabetes caused by vascular damage and aging.
South Korea 365270
Curevac Logo
Pioneering mRNA technology to create vaccines and therapies for infectious diseases, cancer, and more.
Germany CVAC
Curocell Inc. Logo
Biotech developing enhanced CAR-T therapies for cancer using its OVIS™ platform.
South Korea 372320
Cyfuse Biomedical K.K. Logo Japan 4892

Talk to a Data Expert

Have a question? We'll get back to you promptly.